Feline Tetherin is characterized by a short N-Terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein

Journal of Virology

Volumn 86, Issue 12, 2012, Pages 6688-6700

  Celestino, Michele ^a   Calistri, Arianna ^a   Del Vecchio, Claudia ^a   Salata, Cristiano ^a   Chiuppesi, Flavia ^b   Pistello, Mauro ^b   Borsetti, Alessandra ^c   Palù, Giorgio ^a   Parolin, Cristina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CELL PROTEIN; TETHERIN PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL MEMBRANE; FELINE IMMUNODEFICIENCY VIRUS; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS CELL INTERACTION; VIRUS PARTICLE; VIRUS RELEASE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CATS; CELL LINE; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; GPI-LINKED PROTEINS; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS; VIRUS RELEASE;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84864023846     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07037-11     Document Type: Article

References (73)

1. Andrew AJ, Miyagi E, Kao S, Strebel K. 2009. The formation of cysteinelinked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 6:80.
2. Arnaud F, et al. 2010. Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses. J. Virol. 84:4415- 4425.
3. Bendinelli M, et al. 1995. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin. Microbiol. Rev. 8:87-112.
4. Bieniasz PD. 2004. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5:1109 -1115.
5. Blasius AL, et al. 2006. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naïve mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 177: 3260-3265.
6. Brown EW, Yuhki N, Packer C, O'Brien SJ. 1994. A lion lentivirus related to feline immunodeficiency virus: epidemiologic and phylogenetic aspects. J. Virol. 68:5953-5968.
7. Calistri A, et al. 2009. Role of the feline immunodeficiency virus L-domain in the presence or absence of Gag processing: involvement of ubiquitin and Nedd4-2s ligase in viral egress. J. Cell. Physiol. 218:175-182.
8. Carpenter MA, et al. 1996. Genetic and phylogenetic divergence of feline immunodeficiency virus in the puma (Puma concolor). J. Virol. 70:6682- 6693.
9. Chen Z, et al. 1997. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J. Virol. 71:3953-3960.
10. Clavel F, et al. 1986. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324:691- 695.
11. Dietrich I, et al. 2011. Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J. Virol. 85:5840- 5852.
12. Douglas JL, et al. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/tetherin via a betaTrCPdependent mechanism. J. Virol. 83:7931-7947.
13. Dube M, et al. 2009. Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 83:4574-4590.
14. Elder JH, Lin YC, Fink E, Grant CK. 2010. Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr. HIV Res. 1:73- 80.
15. Fadel HJ, Poeschla EM. 2011. Retroviral restriction and dependency factors in primates and carnivores. Vet. Immunol. Immunopathol. 143: 179-189.
16. Fisher AG, Collati E, Ratner L, Gallo RC, Wong-Staal F. 1985. A molecular clone of HTLV-III with biological activity. Nature 316:262- 265.
17. Fukuma A, Abe M, Morikawa Y, Miyazawa T, Yasuda J. 2011. Cloning and characterization of the antiviral activity of feline tetherin/BST-2. PLoS One 6:e18247. doi:10.1371/journal.pone.0018247.
18. Gao F, et al. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397:436-441.
19. Goff SP. 2004. Retrovirus restriction factors. Mol. Cell 16:849-859.
20. Goffinet C, et al. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297.
21. Goffinet C, et al. 2010. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J. Virol. 84:4089-4094.
22. Göttlinger HG, Dorfman T, Sodroski JG, Haseltine WA. 1993. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. U. S. A. 90:7381-7385.
23. Gupta RK, et al. 2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5:e1000443. doi:10.1371/journal.ppat.1000443.
24. Gupta RK, et al. 2009. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U. S. A. 106:20889 -20894.
25. Hahn BH, Shaw GM, De Cock KM, Sharp PM. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287:607- 614.
26. Hauser H, et al. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51.
27. Hofmann-Lehmann R, et al. 1996. Prevalence of antibodies to feline parvovirus, calicivirus, herpesvirus, coronavirus, and immunodeficiency virus and of feline leukemia virus antigen and the interrelationship of these viral infections in free-ranging lions in east Africa. Clin. Diagn. Lab. Immunol. 3:554 -562.
28. Huthoff H, Towers GJ. 2008. Restriction of retroviral replication by APOBEC3G/F and TRIM5alpha. Trends Microbiol. 16:612- 619.
29. Jia B, et al. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5:e1000429. doi: 10.1371/journal.ppat.1000429.
30. Kestler H, et al. 1990. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248:1109 -1112.
31. Le Tortorec A, Neil SJ. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966 -11978.
32. Malim MH, Emerman M. 2008. HIV-1 accessory proteins ensuring viral survival in a hostile environment. Cell Host Microbe 3:388 -398.
33. Mangeat B, et al. 2009. HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5:e1000574. doi:10.1371/journal.ppat.1000574.
34. Masuyama N, et al. 2009. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J. Biol. Chem. 284:15927-15941.
35. McNatt MW, et al. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5:e1000300. doi:10.1371/journal.ppat.1000300.
36. Miyagi E, Andrew AJ, Kao S, Strebel K. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U. S. A. 106:2868 -2873.
37. Neagu MR, et al. 2009. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J. Clin. Invest. 119: 3035-3047.
38. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD. 2006. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2:e39. doi:10.1371/journal.ppat.0020039.
39. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. 2007. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2:193-203.
40. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425- 430.
41. Ohtomo T, et al. 1999. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258:583-591.
42. Pecon-Slattery J, Troyer JL, Johnson WE, O'Brien SJ. 2008. Evolution of feline immunodeficiency virus in Felidae: implications for human health and wildlife ecology. Vet. Immunol. Immunopathol. 123:32- 44.
43. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. 1987. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235:790 -793.
44. Pedersen NC, Yamamoto JK, Ishida T, Hansen H. 1989. Feline immunodeficiency virus infection. Vet. Immunol. Immunopathol. 21:111-129.
45. Perez-Caballero D, et al. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499 -511.
46. Pistello M, et al. 2007. Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes. Genet. Vaccines Ther. 5:8.
47. Pistello M, et al. 2010. Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J. Virol. 84:3845-3856.
48. Poeschla EM, Looney DJ. 1998. CXCR4 is required by a nonprimate lentivirus: heterologous expression of feline immunodeficiency virus in human, rodent, and feline cells. J. Virol. 72:6858-6866.
49. Regier DA, Desrosiers RC. 1990. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses 6:1221-1231.
50. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. 2007. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J. Cell Sci. 21:3850 -3858.
51. Sauter D, et al. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421.
52. Sawyer SL, Emerman M, Malik HS. 2004. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2:e275. doi:10.1371/journal.pbio.0020275.
53. Sawyer SL, Wu LI, Emerman M, Malik HS. 2005. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U. S. A. 102:2832-2837.
54. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. 2011. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 9:46 -57.
55. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
56. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404 -1407.
57. Shimojima M, et al. 2004. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303:1192-1195.
58. Strack B, Calistri A, Accola MA, Palù G, Gottlinger HG. 2000. A role for ubiquitin ligase recruitment in retrovirus release. Proc. Natl. Acad. Sci. U. S. A. 97:13063-13068.
59. Stremlau M, et al. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
60. Tokarev AA, Munguia J, Guatelli JC. 2011. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J. Virol. 85:51- 63.
61. Tomonaga K, et al. 1992. Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. J. Virol. 66:6181- 6185.
62. Troyer JL, et al. 2004. Patterns of feline immunodeficiency virus multiple infection and genome divergence in a free-ranging population of African lions. J. Virol. 78:3777-3791.
63. Troyer JL, et al. 2005. Seroprevalence and genomic divergence of circulating strains of feline immunodeficiency virus among Felidae and Hyaenidae species. J. Virol. 79:8282- 8294.
64. Troyer JL, et al. 2008. FIV cross-species transmission: an evolutionary prospective. Vet. Immunol. Immunopathol. 123:159 -166.
65. Van Damme N, et al. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
66. VandeWoude S, Apetrei C. 2006. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin. Microbiol. Rev. 19:728 -762.
67. Vidal-Laliena M, et al. 2005. Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell. Immunol. 236:6 -16.
68. Wehrly K, Chesebro B. 1997. p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods 12:288 -293.
69. Willett BJ, Flynn JN, Hosie MJ. 1997. FIV infection of the domestic cat: an animal model for AIDS. Immunol. Today 18:182-189.
70. Willett BJ, Hosie MJ, Neil JC, Turner JD, Hoxie JA. 1997. Common mechanism of infection by lentiviruses. Nature 385:587.
71. Wongsrikeao P, Saenz D, Rinkoski T, Otoi T, Poeschla E. 2011. Antiviral restriction factor transgenesis in the domestic cat. Nat. Methods 8:853- 859.
72. Yamamoto JK, et al. 1988. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am. J. Vet. Res. 49:1246 -1258.
73. Zhang F, et al. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67.